Alignment Healthcare Posts Strong Q3 2026 Earnings Amid Industry Challenges
Alignment Healthcare, a leading health insurance provider, reported impressive third-quarter earnings for 2026, despite facing significant industry challenges. The company's CEO, John Kao, and CFO, Jim Head, led the conference call to discuss the results.
In the third quarter, Alignment Healthcare's health plan membership grew by 31% year-over-year, reaching 301,200 members. This growth drove overall revenue to approximately $1.4 billion, a 37% increase from the same period in 2025. The company's adjusted gross profit of $142 million represented an adjusted medical benefit ratio (MBR) of 89.5%, a 240 basis point improvement year-over-year.
However, Alignment Healthcare faced headwinds during the quarter, including greater volatility in claims processing due to its comprehensive claims system migration. The company also experienced an increase in aggressive provider appeals and disputes, which resulted in higher cost trends. Additionally, pockets of higher costs were seen in areas such as catastrophic cases and skilled nursing.
To address these challenges, Alignment Healthcare took swift action to build out a more robust payment integrity function, including prepay claims edits and post-pay review. The company also invested in its clinical programs to ensure systematic application of best practices across its markets. Despite progress made, the company lowered its annual guidance to no less than adjusted gross profit of $575 million and adjusted EBITDA of $100 million, citing continued cost pressures.
"We are pleased with the progress we have made across our multiple initiatives and saw institutional acute cost trends stabilized as we closed out September and entered October," said John Kao, CEO. "However, given the increased trend seen in Q3, we assume that higher costs will continue to weigh on our results for the remainder of the year."
Alignment Healthcare's Q3 2026 earnings demonstrate the company's resilience in the face of industry challenges. While cost pressures remain a concern, the company's proactive approach and investments in its clinical programs position it for long-term success.
